Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE for Delayed Graft Function in Kidney Transplant
NCT02658162Phase 2Withdrawn
- Sponsor
- Prolong Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of Sanguinate in delayed graft function (DGF), sponsored by Prolong Pharmaceuticals. Planned start Feb 2016; status: withdrawn.
02
Drugs
Sanguinate
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02658162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658162.